Citations (209)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (32)
Ahmad Shamabadi, Ali Ahmadzade, Kasra Pirahesh, Alireza Hasanzadeh & Hassan Asadigandomani. (2023) Suicidality risk after using cannabis and cannabinoids: An umbrella review. Dialogues in Clinical Neuroscience 25:1, pages 50-63.
Read now
Read now
José María Prieto González & Carlos Vila Silván. (2021) Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years” accumulated evidence from clinical trials. Expert Review of Neurotherapeutics 21:7, pages 755-778.
Read now
Read now
Michael A Überall. (2020) A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain. Journal of Pain Research 13, pages 399-410.
Read now
Read now
Sven Gottschling, Oyedeji Ayonrinde, Arun Bhaskar, Marc Blockman, Oscar D’Agnone, Danial Schecter, Luis David Suárez Rodríguez, Sherry Yafai & Claude Cyr. (2020) Safety Considerations in Cannabinoid-Based Medicine. International Journal of General Medicine 13, pages 1317-1333.
Read now
Read now
Sven G Meuth, Thomas Henze, Ute Essner, Christiane Trompke & Carlos Vila Silván. (2020) Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial. International Journal of Neuroscience 130:12, pages 1199-1205.
Read now
Read now
Bernardita Soler, Cintia Ramari, Maxime Valet, Ulrik Dalgas & Peter Feys. (2020) Clinical assessment, management, and rehabilitation of walking impairment in MS: an expert review. Expert Review of Neurotherapeutics 20:8, pages 875-886.
Read now
Read now
Yara Dadalti Fragoso, Adriana Carra & Miguel Angel Macias. (2020) Cannabis and multiple sclerosis. Expert Review of Neurotherapeutics 20:8, pages 849-854.
Read now
Read now
Michael A Ueberall, Ute Essner & Gerhard HH Mueller-Schwefe. (2019) Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry. Journal of Pain Research 12, pages 1577-1604.
Read now
Read now
Ziva D. Cooper & Donald I. Abrams. (2019) Considering abuse liability and neurocognitive effects of cannabis and cannabis-derived products when assessing analgesic efficacy: a comprehensive review of randomized-controlled studies. The American Journal of Drug and Alcohol Abuse 45:6, pages 580-595.
Read now
Read now
Peter S. Cogan. (2019) On healthcare by popular appeal: critical assessment of benefit and risk in cannabidiol based dietary supplements. Expert Review of Clinical Pharmacology 12:6, pages 501-511.
Read now
Read now
Jolana Markovà, Ute Essner, Bülent Akmaz, Marcella Marinelli, Christiane Trompke, Arnd Lentschat & Carlos Vila. (2019) Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. International Journal of Neuroscience 129:2, pages 119-128.
Read now
Read now
Marija Darkovska-Serafimovska, Tijana Serafimovska, Zorica Arsova-Sarafinovska, Sasho Stefanoski, Zlatko Keskovski & Trajan Balkanov. (2018) Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases. Journal of Pain Research 11, pages 837-842.
Read now
Read now
Rafael Arroyo González. (2018) A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis. Expert Review of Neurotherapeutics 18:10, pages 785-791.
Read now
Read now
Kate Behm & Prue Morgan. (2018) The effect of symptom-controlling medication on gait outcomes in people with multiple sclerosis: a systematic review. Disability and Rehabilitation 40:15, pages 1733-1744.
Read now
Read now
Mauro Maccarrone, Rafael Maldonado, Miguel Casas, Thomas Henze & Diego Centonze. (2017) Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?. Expert Review of Clinical Pharmacology 10:4, pages 443-455.
Read now
Read now
Tilden Etges, Kari Karolia, Thomas Grint, Adam Taylor, Heather Lauder, Brian Daka & Stephen Wright. (2016) An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray. Therapeutics and Clinical Risk Management 12, pages 1667-1675.
Read now
Read now
Franjo Grotenhermen & Kirsten Müller-Vahl. (2016) Medicinal Uses of Marijuana and Cannabinoids. Critical Reviews in Plant Sciences 35:5-6, pages 378-405.
Read now
Read now
Sven G Meuth, Carlos Vila & Kerry L Dechant. (2015) Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis. Expert Review of Neurotherapeutics 15:8, pages 909-918.
Read now
Read now
Irene Moreno Torres, Antonio J Sanchez & Antonio Garcia-Merino. (2014) Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis. Expert Review of Neurotherapeutics 14:11, pages 1243-1250.
Read now
Read now
Joanna Makowiecka & Karolina Wielgus. (2014) Therapeutic Potential of Cannabinoids—Perspectives for the Future. Journal of Natural Fibers 11:4, pages 283-311.
Read now
Read now
Jürgen Koehler, Wolfgang Feneberg, Martin Meier & Walter Pöllmann. (2014) Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. International Journal of Neuroscience 124:9, pages 652-656.
Read now
Read now
Jürgen Koehler, Maria P Amato, Celia Oreja-Guevara & Jan Lycke. (2013) Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe. Expert Review of Neurotherapeutics 13:sup2, pages 61-66.
Read now
Read now
Carlo Pozzilli. (2013) Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Review of Neurotherapeutics 13:sup2, pages 49-54.
Read now
Read now
Ralf Gold. (2013) Multiple sclerosis spasticity management – key publications. Expert Review of Neurotherapeutics 13:sup2, pages 47-48.
Read now
Read now
Peter Flachenecker. (2013) A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost–effectiveness in Germany. Expert Review of Neurotherapeutics 13:sup1, pages 15-19.
Read now
Read now
Giulio Podda & Cris S Constantinescu. (2012)
Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis. Expert Opinion on Biological Therapy 12:11, pages 1517-1531.
Read now
Read now
Derick Wade. (2012) Evaluation of the safety and tolerability profile of Sativex®: is it reassuring enough?. Expert Review of Neurotherapeutics 12:sup4, pages 9-14.
Read now
Read now
Celia Oreja-Guevara. (2012) Clinical efficacy and effectiveness of Sativex®, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Review of Neurotherapeutics 12:sup4, pages 3-8.
Read now
Read now
John C Ashton. (2011) Emerging treatment options for spasticity in multiple sclerosis – clinical utility of cannabinoids. Degenerative Neurological and Neuromuscular Disease 1, pages 15-23.
Read now
Read now
Philip Robson. (2011) Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opinion on Drug Safety 10:5, pages 675-685.
Read now
Read now
Jaume Sastre-Garriga, Carlos Vila, Stephen Clissold & Xavier Montalban. (2011) THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis. Expert Review of Neurotherapeutics 11:5, pages 627-637.
Read now
Read now
Patrick Vermersch. (2011) Sativex® (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data. Expert Review of Neurotherapeutics 11:sup4, pages 15-19.
Read now
Read now
Articles from other publishers (177)
Dénes Kleiner, István László Horváth, Stefania Bunduc, Dorottya Gergő, Katalin LugosiPéter Fehérvári, Péter Hegyi & Dezső Csupor. (2023) Nabiximols is Efficient as Add-On Treatment for Patients with Multiple
Sclerosis Spasticity Refractory to Standard Treatment: A Systematic
Review and Meta-Analysis of Randomised Clinical Trials. Current Neuropharmacology 21:12, pages 2505-2515.
Crossref
Crossref
Victor Voicu, Felix-Mircea Brehar, Corneliu Toader, Razvan-Adrian Covache-Busuioc, Antonio Daniel Corlatescu, Andrei Bordeianu, Horia Petre Costin, Bogdan-Gabriel Bratu, Luca-Andrei Glavan & Alexandru Vlad Ciurea. (2023) Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy. Biomolecules 13:9, pages 1388.
Crossref
Crossref
Besma Benredjem & Graciela Pineyro. (2023) A type II cannabis extract and a 1:1 blend of Δ(9)-tetrahydrocannabinol and cannabidiol display distinct antinociceptive profiles and engage different endocannabinoid targets when administered into the subarachnoid space. Frontiers in Pharmacology 14.
Crossref
Crossref
Julie Schjødtz Hansen, Stefan Gustavsen, Homayoun Roshanisefat, Matthias Kant, Fin Biering-Sørensen, Claus Andersen, Anna Olsson, Helene Højsgaard Chow, Nasrin Asgari, Julie Richter Hansen, Helle Hvilsted Nielsen, Rikke Middelhede Hansen, Thor Petersen, Annette Bang Oturai, Finn Sellebjerg, Eva Aggerholm Sædder, Helge Kasch, Peter Vestergaard Rasmussen, Nanna Brix Finnerup & Kristina Bacher Svendsen. (2023) Cannabis-Based Medicine for Neuropathic Pain and Spasticity—A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. Pharmaceuticals 16:8, pages 1079.
Crossref
Crossref
Graziella Filippini, Silvia Minozzi, Francesca Borrelli, Michela Cinquini & Kerry Dwan. (2023) Cannabinoids in Symptomatic Treatment for People with Multiple Sclerosis: a Systematic Review of Randomised Studies. Current Physical Medicine and Rehabilitation Reports.
Crossref
Crossref
Jacqueline Nicholas, Fred Lublin, Sylvia Klineova, Joris Berwaerts, Robert Chinnapongse, Daniel Checketts, Sajida Javaid & Joshua R. Steinerman. (2023) Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials. Multiple Sclerosis and Related Disorders 75, pages 104745.
Crossref
Crossref
Valentina Torri Clerici, Laura Brambilla, Paolo Luca Politi, Federica Viggiani, Simone Mercurio, Simone Tonietti, Marco Ronzoni, Sebastiano Giuseppe Crisafulli, Carlo Antozzi, Irene Tramacere, Chiara Redemagni & Paolo Confalonieri. (2023) Nabiximols oromucosal spray in patients with multiple sclerosis-related bladder dysfunction: A prospective study. Multiple Sclerosis and Related Disorders 74, pages 104711.
Crossref
Crossref
Caio Amaral, Carolina Carvalho, Anabel Scaranelo, Kenneth Chapman, Jose Chatkin & Ivone Ferreira. (2023) Cannabis and sleep disorders: not ready for prime time? A qualitative scoping review. Journal of Clinical Sleep Medicine 19:5, pages 975-990.
Crossref
Crossref
Bahareh Abd‐Nikfarjam, Amirhossein Dolati‐Somarin, Vafa Baradaran Rahimi & Vahid Reza Askari. (2023) Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases. BioFactors 49:3, pages 560-583.
Crossref
Crossref
Alan D. BellCaroline MacCallum, Shari MargoleseZach WalshPatrick WrightPaul J. DaeninckEnrico MandarinoGary Lacasse, Jagpaul Kaur DeolLauren de FreitasMichelle St. Pierre, Lynne Belle-IsleMarilou GagnonSian BevanTatiana SanchezStephanie ArltMax Monahan-EllisonJames O'HaraMichael BoivinCecilia Costiniuk, Nancy Chow, Rob Sealey & Lynda Balneaves. (2023) Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions. Cannabis and Cannabinoid Research.
Crossref
Crossref
César Eduardo Fernandes, José Eduardo Lutaif Dolci, Leonardo Sobral Navarro, Marcelo Allevato, Clóvis Francisco Constantino, Rodrigo Pastor Alves Pereira, Carlos Roberto de Mello Rieder, Flávia Torino, Wanderley Marques Bernardo & Antônio Geraldo da Silva. (2023) Cannabis products: medical use. Revista da Associação Médica Brasileira 69:3, pages 358-364.
Crossref
Crossref
Vera Belgers, Jantine G. RöttgeringLinda DouwMartin KleinJohannes C.F. KetPeter M. van de VenThomas WürdingerMyra E. van LindeJohanna M. NiersMarkus WeberMarcel G. Olde RikkertJose Lopez-SendonOscar ArrietaKristina B. SvendsenMarcos H.N. ChagasCarlos M.O. de Almeida, Mathilde C.M. KouwenhovenPhilip C. de Witt Hamer. (2023) Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis. Cannabis and Cannabinoid Research 8:1, pages 41-55.
Crossref
Crossref
Jehad Barakji, Steven Kwasi Korang, Joshua Feinberg, Mathias Maagaard, Ole Mathiesen, Christian Gluud & Janus Christian Jakobsen. (2023) Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis. PLOS ONE 18:1, pages e0267420.
Crossref
Crossref
Divya Vimal, Leonard Clinton D’Souza, Vipin Rai, Samridhi Lal, Anurag Sharma & Subash Chandra Gupta. (2023) Efficacy of Cannabis and its Constituents in Disease Management:
Insights from Clinical Studies. Current Medicinal Chemistry 30:2, pages 178-202.
Crossref
Crossref
Ana I Fraguas-Sánchez & Ana I. Torres-Suárez. 2023. Current Applications, Approaches, and Potential Perspectives for Hemp. Current Applications, Approaches, and Potential Perspectives for Hemp
407
445
.
Igor Dykukha, Ute Essner, Herbert Schreiber, Lina Marie Raithel & Iris-Katharina Penner. (2022) Effects of SativexⓇ on cognitive function in patients with multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders 68, pages 104173.
Crossref
Crossref
Christopher KudrichYasmin L. HurdEdwin SalsitzAn-Li Wang. (2022) Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol. Cannabis and Cannabinoid Research 7:5, pages 569-581.
Crossref
Crossref
Rylea M. RanumMary O. WhippleIvana CroghanBrent BauerLoren L. ToussaintAnn Vincent. (2022) Use of Cannabidiol in the Management of Insomnia: A Systematic Review. Cannabis and Cannabinoid Research.
Crossref
Crossref
Francesco Patti, Clara Grazia Chisari, Óscar Fernández, Jorge Sarroca, Elena Ferrer‐Picón, Francisco Hernández Vicente & Carlos Vila Silván. (2022) A real‐world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described ‘spasticity‐plus syndrome’. European Journal of Neurology 29:9, pages 2744-2753.
Crossref
Crossref
Ainhoa Bilbao & Rainer Spanagel. (2022) Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Medicine 20:1.
Crossref
Crossref
Muhammad Yousaf, Dennis Chang, Yang Liu, Tianqing Liu & Xian Zhou. (2022) Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders. Molecules 27:15, pages 4961.
Crossref
Crossref
Armando Creta, Luana Gilio, Diego Centonze & Roberta Fantozzi. (2022) Usability of an application device for nabiximols oromucosal spray in patients with upper limb impaired multiple sclerosis. Neurodegenerative Disease Management 12:4, pages 195-201.
Crossref
Crossref
Andrew Chan & Carlos Vila Silván. (2022) Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap. Neurodegenerative Disease Management 12:3, pages 141-154.
Crossref
Crossref
Yolanda Paes-Colli, Andrey F. L. Aguiar, Alinny Rosendo Isaac, Bruna K. Ferreira, Raquel Maria P. Campos, Priscila Martins Pinheiro Trindade, Ricardo Augusto de Melo Reis & Luzia S. Sampaio. (2022) Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. Frontiers in Cellular Neuroscience 16.
Crossref
Crossref
Fatma Haddad, Ghadeer Dokmak & Rafik Karaman. (2022) The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms. Life 12:5, pages 682.
Crossref
Crossref
Omar M. E. Abdel-Salam. (2022) The Neurotoxic Effects of Cannabis on Brain: Review of Clinical and Experimental Data. MOLECULAR SCIENCES AND APPLICATIONS 2, pages 11-23.
Crossref
Crossref
Victor Longoria, Hannah Parcel, Bameelia Toma, Annu Minhas & Rana Zeine. (2022) Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination. Biomedicines 10:3, pages 539.
Crossref
Crossref
Mahmood AminiLari, Li Wang, Samuel Neumark, Taranah Adli, Rachel J Couban, Aidan Giangregorio, Colleen E Carney & Jason W Busse. (2022) Medical cannabis and cannabinoids for impaired sleep: a systematic review and meta-analysis of randomized clinical trials. Sleep 45:2.
Crossref
Crossref
Yhojan Rodríguez, Lucas Restrepo, Christopher Chang & Juan-Manuel Anaya. 2022. Allergic and Immunologic Diseases. Allergic and Immunologic Diseases
887
975
.
Marie D’hooghe, Barbara Willekens, Valerie Delvaux, Miguel D’haeseleer, Daniel Guillaume, Guy Laureys, Guy Nagels, Patrick Vanderdonckt, Vincent Van Pesch & Veronica Popescu. (2021) Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience. BMC Neurology 21:1.
Crossref
Crossref
Daniel Erku, Shakti Shrestha & Paul Scuffham. (2021) Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations. Value in Health 24:10, pages 1520-1530.
Crossref
Crossref
Oscar Fernandez, Lucienne Costa-Frossard, Maria Luisa Martínez-Ginés, Paloma Montero, Jose María Prieto-González & Lluís Ramió-Torrentà. (2021) Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat® Methodology. Frontiers in Neurology 12.
Crossref
Crossref
Emma Fisher, R. Andrew Moore, Alexandra E. Fogarty, David P. Finn, Nanna B. Finnerup, Ian Gilron, Simon Haroutounian, Elliot Krane, Andrew S.C. Rice, Michael Rowbotham, Mark Wallace & Christopher Eccleston. (2021) Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain 162:1, pages S45-S66.
Crossref
Crossref
Mark Oppe, Daniela Ortín-Sulbarán, Carlos Vila Silván, Anabel Estévez-Carrillo & Juan M. Ramos-Goñi. (2021) Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses. The European Journal of Health Economics 22:5, pages 711-721.
Crossref
Crossref
Daniel Joseph & Johannes Schulze. (2021) Cannabinoid Activity—Is There a Causal Connection to Spasmolysis in Clinical Studies?. Biomolecules 11:6, pages 826.
Crossref
Crossref
Clayton W. Swanson, Felix Proessl, Jaclyn A. Stephens, Augusto A. Miravalle & Brett W. Fling. (2021) Non-invasive brain stimulation to assess neurophysiologic underpinnings of lower limb motor impairment in multiple sclerosis. Journal of Neuroscience Methods 356, pages 109143.
Crossref
Crossref
Igor Dykukha, Rolf Malessa, Ute Essner & Michael A Überall. (2021) Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials. Pain Medicine 22:4, pages 861-874.
Crossref
Crossref
Friedemann Paul & Carlos Vila Silván. (2021) Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity. Neurodegenerative Disease Management 11:2, pages 143-153.
Crossref
Crossref
Carmen Navarrete, Adela García-Martín, Alain Rolland, Jim DeMesa & Eduardo Muñoz. (2021) Cannabidiol and Other Cannabinoids in Demyelinating Diseases. International Journal of Molecular Sciences 22:6, pages 2992.
Crossref
Crossref
Anup D. Patel. (2021) Cannabinoids in Neurologic Illnesses. Neurologic Clinics 39:1, pages 231-241.
Crossref
Crossref
Michael Boivin. 2021. Cannabinoids and Pain. Cannabinoids and Pain
119
126
.
Clementina Manera & Simone Bertini. 2021. Cannabinoids and Neuropsychiatric Disorders. Cannabinoids and Neuropsychiatric Disorders
111
129
.
Shannon Inglet, Bradly Winter, Sarah E. Yost, Sophia Entringer, Anh Lian, Meryl Biksacky, Renee D. Pitt & Whitney Mortensen. (2020) Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature. Annals of Pharmacotherapy 54:11, pages 1109-1143.
Crossref
Crossref
Alessandra SolariAndrea GiordanoJaume Sastre-GarrigaSascha KöpkeAnne C. RahnIngo KleiterKatina AleksovskaMario A. BattagliaJette BayMassimiliano CopettiJelena DrulovicLiesbeth KooijJohn MensEdwin R. Meza MurilloIvan MilanovRon MiloTatiana PekmezovicJanine VosburghEli SilberSimone VeroneseFrancesco PattiRaymond VoltzDavid J. Oliver. (2020) EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis. Journal of Palliative Medicine 23:11, pages 1426-1443.
Crossref
Crossref
Francesco Patti, Clara Grazia Chisari, Claudio Solaro, Maria Donata Benedetti, Eliana Berra, Assunta Bianco, Roberto Bruno Bossio, Fabio Buttari, Letizia Castelli, Paola Cavalla, Raffaella Cerqua, Gianfranco Costantino, Claudio Gasperini, Angelica Guareschi, Domenico Ippolito, Roberta Lanzillo, Giorgia Teresa Maniscalco, Manuela Matta, Damiano Paolicelli, Loredana Petrucci, Simona Pontecorvo, Isabella Righini, Margherita Russo, Francesco Saccà, Giovanna Salamone, Elisabetta Signoriello, Gabriella Spinicci, Daniele Spitaleri, Eleonora Tavazzi, Maria Trotta, Mauro Zaffaroni & Mario Zappia. (2020) Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study. Neurological Sciences 41:10, pages 2905-2913.
Crossref
Crossref
Clara Grazia Chisari, Claudio Solaro, Pasquale Annunziata, Roberto Bergamaschi, Assunta Bianco, Simona Bonavita, Vincenzo Brescia Morra, Roberto Bruno Bossio, Elisabetta Capello, Letizia Castelli, Paola Cavalla, Gianfranco Costantino, Diego Centonze, Salvatore Cottone, Maura Chiara Danni, Federica Esposito, Alberto Gajofatto, Claudio Gasperini, Angelica Guareschi, Roberta Lanzillo, Giacomo Lus, Giorgia Teresa Maniscalco, Manuela Matta, Damiano Paolicelli, Loredana Petrucci, Simona Pontecorvo, Isabella Righini, Marco Rovaris, Edoardo Sessa, Gabriella Spinicci, Daniele Spitaleri, Paola Valentino, Mauro Zaffaroni, Mario Zappia & Francesco Patti. (2020) Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. Journal of Neurology, Neurosurgery & Psychiatry 91:9, pages 914-920.
Crossref
Crossref
A. Solari, A. Giordano, J. Sastre‐Garriga, S. Köpke, A. C. Rahn, I. Kleiter, K. Aleksovska, M. A. Battaglia, J. Bay, M. Copetti, J. Drulovic, L. Kooij, J. Mens, E. R. Meza Murillo, I. Milanov, R. Milo, T. Pekmezovic, J. Vosburgh, E. Silber, S. Veronese, F. Patti, R. Voltz & D. Oliver. (2020) EAN guideline on palliative care of people with severe, progressive multiple sclerosis. European Journal of Neurology 27:8, pages 1510-1529.
Crossref
Crossref
Zaid H. Maayah, Shingo Takahara, Mourad Ferdaoussi & Jason R.B. Dyck. (2020) The molecular mechanisms that underpin the biological benefits of full-spectrum cannabis extract in the treatment of neuropathic pain and inflammation. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1866:7, pages 165771.
Crossref
Crossref
Zaid H. Maayah, Shingo Takahara, Mourad Ferdaoussi & Jason R. B. Dyck. (2020) The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiple sclerosis. Inflammation Research 69:6, pages 549-558.
Crossref
Crossref
Kent A. Owusu, Lina Saliba, Abdalla A. Ammar, Mahmoud A. Ammar & Jeffrey Mucksavage. (2020) Application of Cannabinoids in Neurosciences. Critical Care Nursing Quarterly 43:2, pages 216-231.
Crossref
Crossref
Mohammed M. Mohiuddin, Glenio B. Mizubuti, Simon Haroutounian, Shannon M. Smith, Andrew S.C. Rice, Fiona Campbell, Rex Park & Ian Gilron. (2020) Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Medical Cannabis and Cannabis-based Medicines for Chronic Noncancer Pain. The Clinical Journal of Pain 36:4, pages 302-319.
Crossref
Crossref
Óscar Fernández, Lucienne Costa-Frossard, Marisa Martínez-Ginés, Paloma Montero, José Maria Prieto & Lluis Ramió. (2020) The Broad Concept of “Spasticity-Plus Syndrome” in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms. Frontiers in Neurology 11.
Crossref
Crossref
Katarina Černe. (2020)
Toxicological properties of Δ
9
-tetrahydrocannabinol and cannabidiol
. Archives of Industrial Hygiene and Toxicology 71:1, pages 1-11.
Crossref
Crossref
G. Comi, A. Solari, L. Leocani, D. Centonze & S. Otero‐Romero. (2019) Italian consensus on treatment of spasticity in multiple sclerosis. European Journal of Neurology 27:3, pages 445-453.
Crossref
Crossref
James M. NicholsBarbara L.F. Kaplan. (2020) Immune Responses Regulated by Cannabidiol. Cannabis and Cannabinoid Research 5:1, pages 12-31.
Crossref
Crossref
Sharon R. Sznitman, Tamar Shochat & Talya Greene. (2020) Is time elapsed between cannabis use and sleep start time associated with sleep continuity? An experience sampling method. Drug and Alcohol Dependence 208, pages 107846.
Crossref
Crossref
Katarzyna Ziętal, Ilona Joniec-Maciejak & Dagmara Mirowska-Guzel. (2020) Current state of knowledge on the use of medical marijuana in some neurological diseases. Pharmacotherapy in Psychiatry and Neurology 36:3, pages 205-225.
Crossref
Crossref
Herman Johal, Christopher Vannabouathong, Yaping Chang, Meng Zhu & Mohit Bhandari. (2020) Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use?. Therapeutic Advances in Musculoskeletal Disease 12, pages 1759720X2093796.
Crossref
Crossref
Seulah Choi, Barry C. Huang & Charlene E. Gamaldo. (2020) Therapeutic Uses of Cannabis on Sleep Disorders and Related Conditions. Journal of Clinical Neurophysiology 37:1, pages 39-49.
Crossref
Crossref
Tyler E. Gaston, Jerzy P. Szaflarski, Allen C. Bowling, Ying Liu, Tristan Seawalt, Maureen A. Leehey, E. Lee Nelson, Sharad Rajpal, Alan T. Villavicencio, Andrew Bauer & Sigita Burneikiene. 2020. Cannabis in Medicine. Cannabis in Medicine
231
312
.
Massimo Filippi & Maria A. RoccaMassimo Filippi & Maria A. Rocca. 2020. White Matter Diseases. White Matter Diseases
1
35
.
Ivan Urits, Leena Adamian, Jacob Fiocchi, Dylan Hoyt, Carly Ernst, Alan D. Kaye & Omar Viswanath. (2019) Advances in the Understanding and Management of Chronic Pain in Multiple Sclerosis: a Comprehensive Review. Current Pain and Headache Reports 23:8.
Crossref
Crossref
Kazuhito Watanabe, Noriyuki Usami, Shigehiro Osada, Shizuo Narimatsu, Ikuo Yamamoto & Hidetoshi Yoshimura. (2019) Cannabidiol metabolism revisited: tentative identification of novel decarbonylated metabolites of cannabidiol formed by human liver microsomes and recombinant cytochrome P450 3A4. Forensic Toxicology 37:2, pages 449-455.
Crossref
Crossref
Suzanne Nielsen, Bridin Murnion, Gabrielle Campbell, Helen Young & Wayne Hall. (2019) Cannabinoids for the treatment of spasticity. Developmental Medicine & Child Neurology 61:6, pages 631-638.
Crossref
Crossref
Daniel Friedman, Jacqueline A French & Mauro Maccarrone. (2019) Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders. The Lancet Neurology 18:5, pages 504-512.
Crossref
Crossref
Rui Rodrigues, Diogo Lourenço, Sara Paulo, Joana Mateus, Miguel Ferreira, Francisco Mouro, João Moreira, Filipa Ribeiro, Ana Sebastião & Sara Xapelli. (2019) Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology. Molecules 24:7, pages 1350.
Crossref
Crossref
Nilo Riva, Gabriele Mora, Gianni Sorarù, Christian Lunetta, Ottavia E Ferraro, Yuri Falzone, Letizia Leocani, Raffaella Fazio, Mauro Comola, Giancarlo Comi, Fabio Formaglio, Paolo Rossi, Marta Clerici, Yuri Matteo Falzone, Laura Pozzi, Daniele Martinelli, Federica Cerri, Ignazio Diego Lopez, Filippo Martinelli-Boneschi, Angelo Quattrini, Elisabetta Pieri, Kalliopi Marinou, Giorgia Querin, Valeria Sansone, Eleonora Maestri, Andrea Calvo & Adriano Chio. (2019) Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology 18:2, pages 155-164.
Crossref
Crossref
Katja Akgün, Ute Essner, Cordula Seydel & Tjalf Ziemssen. (2019) Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies. Journal of Central Nervous System Disease 11, pages 117957351983199.
Crossref
Crossref
Eva Hoch, Miriam Schneider, Rupert von Keller, Udo Bonnet, Peter Falkai, Alkomiet Hasan, Winfried Häuser, Burkhard Hinz, Luise Jakob, Johannes Kabisch, Ludwig Kraus, Dominik Niemann, Frank Petzke, Oliver Pogarell, Ulrich Preuss, Lukas Radbruch, Nina Sarubin, Kathrin Schacherbauer, Michael Schäfer, Martin Storr & Chris Maria Friemel. 2019. Cannabis: Potenzial und Risiko. Cannabis: Potenzial und Risiko
265
426
.
Eric P. Baron, Philippe Lucas, Joshua Eades & Olivia Hogue. (2018) Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. The Journal of Headache and Pain 19:1.
Crossref
Crossref
Massimo Filippi, Amit Bar-Or, Fredrik Piehl, Paolo Preziosa, Alessandra Solari, Sandra Vukusic & Maria A. Rocca. (2018) Multiple sclerosis. Nature Reviews Disease Primers 4:1.
Crossref
Crossref
Marc O. Martel, Yoram Shir & Mark A. Ware. (2018) Substance-related disorders: A review of prevalence and correlates among patients with chronic pain. Progress in Neuro-Psychopharmacology and Biological Psychiatry 87, pages 245-254.
Crossref
Crossref
Ana Isabel Fraguas-Sánchez & Ana Isabel Torres-Suárez. (2018) Medical Use of Cannabinoids. Drugs 78:16, pages 1665-1703.
Crossref
Crossref
Mari Carmen Torres-Moreno, Esther Papaseit, Marta Torrens & Magí Farré. (2018) Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis. JAMA Network Open 1:6, pages e183485.
Crossref
Crossref
Emily Stockings, Gabrielle Campbell, Wayne D. Hall, Suzanne Nielsen, Dino Zagic, Rakin Rahman, Bridin Murnion, Michael Farrell, Megan Weier & Louisa Degenhardt. (2018) Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain 159:10, pages 1932-1954.
Crossref
Crossref
Francesca Gado, Maria Digiacomo, Marco Macchia, Simone Bertini & Clementina Manera. (2018) Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis. Medicines 5:3, pages 91.
Crossref
Crossref
Peter Riedel & Michael H. Marino. (2018) Pharmacologic Treatment Tools. Physical Medicine and Rehabilitation Clinics of North America 29:3, pages 501-517.
Crossref
Crossref
Jessica Rice & Michelle Cameron. (2018) Cannabinoids for Treatment of MS Symptoms: State of the Evidence. Current Neurology and Neuroscience Reports 18:8.
Crossref
Crossref
Peter Flachenecker, Francesco Saccà & Carlos Vila. (2018) Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings. Case Reports in Neurology 10:2, pages 169-176.
Crossref
Crossref
Eric P. Baron. (2018) Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache: The Journal of Head and Face Pain 58:7, pages 1139-1186.
Crossref
Crossref
. (2018) Appendix C: References (Part I). Journal of Nursing Regulation 9:2, pages S52-S58.
Crossref
Crossref
. (2018) Appendix B: Quality Research, Evidence of Effectiveness of Medical Cannabis. Journal of Nursing Regulation 9:2, pages S47-S51.
Crossref
Crossref
. (2018) APRNs Certifying a Medical Marijuana Qualifying Condition. Journal of Nursing Regulation 9:2, pages S39-S45.
Crossref
Crossref
. (2018) Medical Marijuana Education in APRN Nursing Programs. Journal of Nursing Regulation 9:2, pages S33-S38.
Crossref
Crossref
. (2018) Medical Marijuana Education in Pre-Licensure Nursing Programs. Journal of Nursing Regulation 9:2, pages S28-S32.
Crossref
Crossref
. (2018) Nursing Care of the Patient Using Medical Marijuana. Journal of Nursing Regulation 9:2, pages S23-S27.
Crossref
Crossref
. (2018) Adverse Effects of Cannabis. Journal of Nursing Regulation 9:2, pages S14-S17.
Crossref
Crossref
. (2018) Part I: Current Legislation, Scientific Literature Review, and Nursing Implications. Journal of Nursing Regulation 9:2, pages S6-S21.
Crossref
Crossref
Javier Mallada Frechín. (2018) Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study. Neurodegenerative Disease Management 8:3, pages 151-159.
Crossref
Crossref
Xiying Fu, Yanqiao Wang, Can Wang, Huijie Wu, Jinyao Li, Ming Li, Qianqian Ma & Wei Yang. (2018) A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis. Clinical Rehabilitation 32:6, pages 713-721.
Crossref
Crossref
Deanna TeohThomas J. SmithMihae SongNick M. Spirtos. (2018) Care After Chemotherapy: Peripheral Neuropathy, Cannabis for Symptom Control, and Mindfulness. American Society of Clinical Oncology Educational Book:38, pages 469-479.
Crossref
Crossref
Elisabeth G. Celius & Carlos Vila. (2018)
The influence of
THC
:
CBD
oromucosal spray on driving ability in patients with multiple sclerosis‐related spasticity
. Brain and Behavior 8:5.
Crossref
Crossref
Suzanne Nielsen, Rada Germanos, Megan Weier, John Pollard, Louisa Degenhardt, Wayne Hall, Nicholas Buckley & Michael Farrell. (2018) The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Current Neurology and Neuroscience Reports 18:2.
Crossref
Crossref
Mark A. Ware, Marc O. Martel, Roman Jovey, Mary E. Lynch & Joel Singer. (2017) A prospective observational study of problematic oral cannabinoid use. Psychopharmacology 235:2, pages 409-417.
Crossref
Crossref
Bryan Tungland. 2018. Human Microbiota in Health and Disease. Human Microbiota in Health and Disease
517
594
.
Samuel Herzog, Marian Shanahan, Peter Grimison, Anh Tran, Nicole Wong, Nicholas Lintzeris, John Simes, Martin Stockler & Rachael L. Morton. (2017) Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis. PharmacoEconomics 36:1, pages 67-78.
Crossref
Crossref
Giorgia Teresa Maniscalco, R. Aponte, D. Bruzzese, G. Guarcello, V. Manzo, M. Napolitano, O. Moreggia, F. Chiariello & C. Florio. (2017) THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study. Neurological Sciences 39:1, pages 97-102.
Crossref
Crossref
Steven M. Bailey & Claire M. Rice. 2018. Progressive Multiple Sclerosis. Progressive Multiple Sclerosis
155
205
.
Tarek Nafee, Rodrigo Watanabe & Felipe Fregni. 2018. Clinical Trials in Neurology. Clinical Trials in Neurology
263
295
.
T. Henze, W. Feneberg, P. Flachenecker, D. Seidel, H. Albrecht, M. Starck & S. G. Meuth. (2017) Neues zur symptomatischen MS‑Therapie: Teil 2 – Gangstörung und SpastikWhat is new in symptomatic MS treatment: Part 2—gait disorder and spasticity. Der Nervenarzt 88:12, pages 1428-1434.
Crossref
Crossref
Guillermo Izquierdo. (2017) Multiple sclerosis symptoms and spasticity management: new data. Neurodegenerative Disease Management 7:6s, pages 7-11.
Crossref
Crossref
Sabrina Giacoppo, Placido Bramanti & Emanuela Mazzon. (2017) Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation. Multiple Sclerosis and Related Disorders 17, pages 22-31.
Crossref
Crossref
Victoria P. da Rovare, Gabriel P.A. Magalhães, Guilherme D.A. Jardini, Matheus L. Beraldo, Mariel O. Gameiro, Arnav Agarwal, Gustavo José Luvizutto, Lucas Paula-Ramos, Samira Esteves Afonso Camargo, Luciane Dias de Oliveira, Rodrigo Bazan & Regina El Dib. (2017) Cannabinoids for spasticity due to multiple sclerosis or paraplegia: A systematic review and meta-analysis of randomized clinical trials. Complementary Therapies in Medicine 34, pages 170-185.
Crossref
Crossref
Mohammad Hosein Farzaei, Zahra Shahpiri, Roodabeh Bahramsoltani, Marjan Moghaddam nia, Fariba Najafi & Roja Rahimi. (2017) Efficacy and Tolerability of Phytomedicines in Multiple Sclerosis Patients: A Review. CNS Drugs 31:10, pages 867-889.
Crossref
Crossref
Silvia Messina, Claudio Solaro, Isabella Righini, Roberto Bergamaschi, Simona Bonavita, Roberto Bruno Bossio, Vincenzo Brescia Morra, Gianfranco Costantino, Paola Cavalla, Diego Centonze, Giancarlo Comi, Salvatore Cottone, Maura Chiara Danni, Ada Francia, Alberto Gajofatto, Claudio Gasperini, Mauro Zaffaroni, Loredana Petrucci, Elisabetta Signoriello, Giorgia Teresa Maniscalco, Gabriella Spinicci, Manuela Matta, Massimiliano Mirabella, Graziella Pedà, Letizia Castelli, Marco Rovaris, Edoardo Sessa, Daniele Spitaleri, Damiano Paolicelli, Alfredo Granata, Mario Zappia & Francesco Patti. (2017) Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). PLOS ONE 12:8, pages e0180651.
Crossref
Crossref
Massimo Santoro, Massimiliano Mirabella, Chiara De Fino, Assunta Bianco, Matteo Lucchini, Francesco Losavio, Andrea Sabino & Viviana Nociti. (2017) Sativex® effects on promoter methylation and on CNR1 / CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients. Journal of the Neurological Sciences 379, pages 298-303.
Crossref
Crossref
Matthew Goldenberg, Mark William Reid, Waguih William IsHak & Itai Danovitch. (2017) The impact of cannabis and cannabinoids for medical conditions on health-related quality of life: A systematic review and meta-analysis. Drug and Alcohol Dependence 174, pages 80-90.
Crossref
Crossref
A. Carotenuto, R. Iodice, M. Petracca, M. Inglese, I. Cerillo, S. Cocozza, C. Saiote, A. Brunetti, E. Tedeschi, F. Manganelli & G. Orefice. (2017)
Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex
?
. Acta Neurologica Scandinavica 135:4, pages 442-448.
Crossref
Crossref
Gillian M. Keating. (2017) Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity. Drugs 77:5, pages 563-574.
Crossref
Crossref
Melanie E. M. Kelly, Christian Lehmann & Juan Zhou. (2017) The Endocannabinoid System in Local and Systemic Inflammation. Colloquium Series on Integrated Systems Physiology: From Molecule to Function 9:2, pages i-192.
Crossref
Crossref
G. Illomei, G. Spinicci, E. Locci & M. G. Marrosu. (2016) Muscle elastography: a new imaging technique for multiple sclerosis spasticity measurement. Neurological Sciences 38:3, pages 433-439.
Crossref
Crossref
Georgia Watt & Tim Karl. (2017) In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease. Frontiers in Pharmacology 8.
Crossref
Crossref
Giuseppe Lanza, Raffaele Ferri, Rita Bella & Luigi Ferini-Strambi. (2016) The impact of drugs for multiple sclerosis on sleep. Multiple Sclerosis Journal 23:1, pages 5-13.
Crossref
Crossref
John C. Ashton, Megan J. Dowie & Michelle Glass. 2017. The Endocannabinoid System. The Endocannabinoid System
115
186
.
Angelo Ghezzi, Linard Filli, Claudio Solaro, Claude Mekies, Lamberto Landete & Jan Lycke. (2016) Country breakout session highlights. Neurodegenerative Disease Management 6:6s, pages 41-44.
Crossref
Crossref
Peter Flachenecker. (2016) Evolution of multiple sclerosis spasticity-associated symptoms: latest data. Neurodegenerative Disease Management 6:6s, pages 9-12.
Crossref
Crossref
Giovanna Squintani, Francesco Donato, Mara Turri, Luciano Deotto, Francesco Teatini, Giuseppe Moretto & Roberto Erro. (2016) Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray. Journal of the Neurological Sciences 370, pages 263-268.
Crossref
Crossref
Michaela Kuhlen, Jessica I. Hoell, Gabriele Gagnon, Stefan Balzer, Prasad T. Oommen, Arndt Borkhardt & Gisela Janßen. (2016) Effective treatment of spasticity using dronabinol in pediatric palliative care. European Journal of Paediatric Neurology 20:6, pages 898-903.
Crossref
Crossref
Ethan B. Russo. (2016) Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. Frontiers in Pharmacology 7.
Crossref
Crossref
F Patti, S Messina, C Solaro, M P Amato, R Bergamaschi, S Bonavita, R Bruno Bossio, V Brescia Morra, G F Costantino, P Cavalla, D Centonze, G Comi, S Cottone, M Danni, A Francia, A Gajofatto, C Gasperini, A Ghezzi, A Iudice, G Lus, G T Maniscalco, M G Marrosu, M Matta, M Mirabella, E Montanari, C Pozzilli, M Rovaris, E Sessa, D Spitaleri, M Trojano, P Valentino & M Zappia. (2016) Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Journal of Neurology, Neurosurgery & Psychiatry 87:9, pages 944-951.
Crossref
Crossref
Francesco Sacc?, Chiara Pane, Antonio Carotenuto, Marco Massarelli, Roberta Lanzillo, Ettore Brunello Florio & Vincenzo Brescia Morra. (2016) The use of medical-grade cannabis in patients non-responders to Nabiximols. Journal of the Neurological Sciences 368, pages 349-351.
Crossref
Crossref
Kelly Andrzejewski, Richard Barbano & Jonathan Mink. (2016) Cannabinoids in the treatment of movement disorders: A systematic review of case series and clinical trials. Basal Ganglia 6:3, pages 173-181.
Crossref
Crossref
Damiano Paolicelli, Vita Direnzo, Alessia Manni, Mariangela D'Onghia, Carla Tortorella, Stefano Zoccolella, Valentina Di Lecce, Antonio Iaffaldano & Maria Trojano. (2016) Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients. The Journal of Clinical Pharmacology 56:7, pages 845-851.
Crossref
Crossref
Danielle Morabito, Peter Soyster, Shaw Ramey-Wright, Katherine A. Belendiuk & Marcel O. Bonn-Miller. (2016) A Review of Recent Advances in the Therapeutic Uses of Secondary Cannabinoids. Current Addiction Reports 3:2, pages 230-238.
Crossref
Crossref
Chaela S. Presley, Ammaar H. Abidi & Bob M. MooreIIII. (2016) Cannabinoid receptor 1 ligands revisited: Pharmacological assessment in the ACTOne system. Analytical Biochemistry 498, pages 8-28.
Crossref
Crossref
Laura Ferrè, Arturo Nuara, Giulia Pavan, Marta Radaelli, Lucia Moiola, Mariaemma Rodegher, Bruno Colombo, Ignacio Juan Keller Sarmiento, Vittorio Martinelli, Letizia Leocani, Filippo Martinelli Boneschi, Giancarlo Comi & Federica Esposito. (2015) Efficacy and safety of nabiximols (Sativex®) on multiple sclerosis spasticity in a real-life Italian monocentric study. Neurological Sciences 37:2, pages 235-242.
Crossref
Crossref
Katarina Vesic, Slavica Djukic Dejanovic, Milica Borovcanin, Janko Samardzic & Gordana Toncev. (2016) Cannabis as a Possible Treatment for Spasticity in Multiple Sclerosis / Kanabis Kao Moguci Tretman U Lecenju Spasticnosti Kod Multiple Skleroze. Serbian Journal of Experimental and Clinical Research 17:1.
Crossref
Crossref
Uwe K. Zettl, Paulus Rommer, Petra Hipp & Robert Patejdl. (2015) Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Therapeutic Advances in Neurological Disorders 9:1, pages 9-30.
Crossref
Crossref
Hardeep Chohan, Ariele L. Greenfield, Vijayshree Yadav & Jennifer Graves. (2015) Use of Cannabinoids for Spasticity and Pain Management in MS. Current Treatment Options in Neurology 18:1.
Crossref
Crossref
Franz Fazekas, Klaus Gehring, Paolo Gallo, Christine Lebrun-Frénay, Ester Moral & Kjell-Morten Myhr. (2015) Country break-out session highlights. Neurodegenerative Disease Management 5:6s, pages 31-37.
Crossref
Crossref
Letizia Leocani, Arturo Nuara, Elise Houdayer, Irene Schiavetti, Ubaldo Del Carro, Stefano Amadio, Laura Straffi, Paolo Rossi, Vittorio Martinelli, Carlos Vila, Maria Pia Sormani & Giancarlo Comi. (2015) Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis. Journal of Neurology 262:11, pages 2520-2527.
Crossref
Crossref
William G. Notcutt. (2015) Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis. Neurotherapeutics 12:4, pages 769-777.
Crossref
Crossref
Eric P. Baron. (2015) Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been …. Headache: The Journal of Head and Face Pain 55:6, pages 885-916.
Crossref
Crossref
C. Lebrun & P. Vermersch. (2015) Une avancée pour la prise en charge de la spasticité dans la sclérose en plaques. Revue Neurologique 171:4, pages 327-328.
Crossref
Crossref
Vincenzo Di Marzo & Diego Centonze. (2015) Placebo Effects in a Multiple Sclerosis Spasticity Enriched Clinical Trial with the Oromucosal Cannabinoid Spray (THC/CBD): Dimension and Possible Causes. CNS Neuroscience & Therapeutics 21:3, pages 215-221.
Crossref
Crossref
Timothy J England, William H Hind, Nadiah A Rasid & Saoirse E O'Sullivan. (2015) Cannabinoids in Experimental Stroke: A Systematic Review and Meta-Analysis. Journal of Cerebral Blood Flow & Metabolism 35:3, pages 348-358.
Crossref
Crossref
Benzi Kluger, Piera Triolo, Wallace Jones & Joseph Jankovic. (2015) The therapeutic potential of cannabinoids for movement disorders. Movement Disorders 30:3, pages 313-327.
Crossref
Crossref
Maria Trojano & Carlos Vila. (2015) Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study. European Neurology 74:3-4, pages 178-185.
Crossref
Crossref
M. Freidel, K. Tiel-Wilck, H. Schreiber, A. Prechtl, U. Essner & M. Lang. (2015)
Drug-resistant MS spasticity treatment with Sativex
®
add-on and driving ability
. Acta Neurologica Scandinavica 131:1, pages 9-16.
Crossref
Crossref
Peter J. Gates, Lucy Albertella & Jan Copeland. (2014) The effects of cannabinoid administration on sleep: a systematic review of human studies. Sleep Medicine Reviews 18:6, pages 477-487.
Crossref
Crossref
Vijayshree Yadav & Pushpa Narayanaswami. (2014) Complementary and Alternative Medical Therapies in Multiple Sclerosis–The American Academy of Neurology Guidelines: A Commentary. Clinical Therapeutics 36:12, pages 1972-1978.
Crossref
Crossref
Stephen Wright. (2014) Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 83:16, pages 1484-1486.
Crossref
Crossref
M. Serpell, S. Ratcliffe, J. Hovorka, M. Schofield, L. Taylor, H. Lauder & E. Ehler. (2014) A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain 18:7, pages 999-1012.
Crossref
Crossref
Rafael Arroyo, Carlos Vila & Kerry L Dechant. (2014)
Impact of Sativex
®
on quality of life and activities of daily living in patients with multiple sclerosis spasticity
. Journal of Comparative Effectiveness Research 3:4, pages 435-444.
Crossref
Crossref
Omar M. E. Abdel-Salam, Somaia A. Nada, Neveen A. Salem, Marawa El-Sayed El-Shamarka & Enayat Omara. (2013) Effect of Cannabis sativa on oxidative stress and organ damage after systemic endotoxin administration in mice. Comparative Clinical Pathology 23:4, pages 1069-1085.
Crossref
Crossref
Kurt Samson. (2014) LEGAL-EASE. Neurology Today 14:12, pages 18-19.
Crossref
Crossref
Kurt Samson. (2014) AAN SYSTEMATIC REVIEW. Neurology Today 14:9, pages 1.
Crossref
Crossref
Barbara S. KoppelJohn C.M. BrustTerry FifeJeff BronsteinSarah YoussofGary GronsethDavid Gloss. (2014) Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders. Neurology 82:17, pages 1556-1563.
Crossref
Crossref
Yahiya Y. Syed, Kate McKeage & Lesley J. Scott. (2014) Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis. Drugs 74:5, pages 563-578.
Crossref
Crossref
Vijayshree YadavChristopher BeverJrJrJames BowenAllen BowlingBianca Weinstock-GuttmanMichelle CameronDennis BourdetteGary S. GronsethPushpa Narayanaswami. (2014) Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis. Neurology 82:12, pages 1083-1092.
Crossref
Crossref
Oscar Fernández. (2014) Advances in the Management of Multiple Sclerosis Spasticity: Recent Clinical Trials. European Neurology 72:Suppl. 1, pages 9-11.
Crossref
Crossref
Peter Flachenecker, Thomas Henze & Uwe K. Zettl. (2014) Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice. European Neurology 72:1-2, pages 95-102.
Crossref
Crossref
Jürgen Koehler. (2014) Who Benefits Most from THC:CBD Spray? Learning from Clinical Experience. European Neurology 71:Suppl. 1, pages 10-15.
Crossref
Crossref
Tiina Rekand. (2014) THC:CBD Spray and MS Spasticity Symptoms: Data from Latest Studies. European Neurology 71:Suppl. 1, pages 4-9.
Crossref
Crossref
Peter Flachenecker, Thomas Henze & Uwe K. Zettl. (2014) Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity. European Neurology 71:5-6, pages 271-279.
Crossref
Crossref
Anke Stroet, Nadine Trampe & Andrew Chan. (2013) Treatment failure of intrathecal baclofen and supra-additive effect of nabiximols in multiple sclerosis-related spasticity: a case report. Therapeutic Advances in Neurological Disorders 6:3, pages 199-203.
Crossref
Crossref
Rongrong Jiang, Satoshi Yamaori, Yasuka Okamoto, Ikuo Yamamoto & Kazuhito Watanabe. (2013) Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19. Drug Metabolism and Pharmacokinetics 28:4, pages 332-338.
Crossref
Crossref
Lanting Lu, Hilary Pearce, Chris Roome, James Shearer, Iain A. Lang & Ken Stein. (2012) Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis. PharmacoEconomics 30:12, pages 1157-1171.
Crossref
Crossref
Stephen Wright, Paul Duncombe & Douglas G Altman. (2012) Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex?) in people with multiple sclerosis: a new approach. Trials 13:1.
Crossref
Crossref
Serafin Beer, Fary Khan & Jürg Kesselring. (2012) Rehabilitation interventions in multiple sclerosis: an overview. Journal of Neurology 259:9, pages 1994-2008.
Crossref
Crossref
A. Hilliard, C. Stott, S. Wright, G. Guy, G. Pryce, S. Al-Izki, C. Bolton & G. Giovannoni. (2012) Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis. ISRN Neurology 2012, pages 1-7.
Crossref
Crossref
Caroline D'Arcy. (2012) Multiple sclerosis: symptom management. Nursing and Residential Care 14:8, pages 405-409.
Crossref
Crossref
A. Caprioli, R. Coccurello, C. Rapino, S. Di Serio, M. Di Tommaso, M. Vertechy, V. Vacca, N. Battista, F. Pavone, M. Maccarrone & F. Borsini. (2012) The Novel Reversible Fatty Acid Amide Hydrolase Inhibitor ST4070 Increases Endocannabinoid Brain Levels and Counteracts Neuropathic Pain in Different Animal Models. Journal of Pharmacology and Experimental Therapeutics 342:1, pages 188-195.
Crossref
Crossref
Eva de Lago, Miguel Moreno-Martet, Ana Cabranes, José A. Ramos & Javier Fernández-Ruiz. (2012) Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology 62:7, pages 2299-2308.
Crossref
Crossref
Sonia Sevilla Guerra. (2012) Are cannabinoids more effective than placebo in decreasing MS-related bladder dysfunction?. British Journal of Neuroscience Nursing 8:2, pages 71-78.
Crossref
Crossref
David Baker, Gareth Pryce, Samuel J. Jackson, Chris Bolton & Gavin Giovannoni. (2012) The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Multiple Sclerosis and Related Disorders 1:2, pages 64-75.
Crossref
Crossref
Sten Fredrikson & Jan HillertYuval KarmonBijal MehtaBianca Weinstock-Guttman. 2012. Emerging Oral Medications for Multiple Sclerosis. Emerging Oral Medications for Multiple Sclerosis
54
67
.
W Notcutt, R Langford, P Davies, S Ratcliffe & R Potts. (2011) A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Multiple Sclerosis Journal 18:2, pages 219-228.
Crossref
Crossref
Displaying 200 of 209 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list